Prolonged survival in advanced thymoma: effectiveness of sequential multiple lines of chemotherapy in an inoperable case
- Authors:
- Manuela Bergonzi
- Giulio Orlandoni
- Franco Corbella
- Paolo G. Gobbi
View Affiliations
Affiliations: Medicina Interna e Gastroenterologia, Università di Pavia, Fondazione IRCCS Policlinico S. Matteo, 27100 Pavia, Italy, Cardiochirurgia, Università di Pavia, Fondazione IRCCS Policlinico S. Matteo, 27100 Pavia, Italy, Radioterapia Oncologica, Università di Pavia, Fondazione IRCCS Policlinico S. Matteo, 27100 Pavia, Italy
- Published online on: March 21, 2011 https://doi.org/10.3892/ol.2011.282
-
Pages:
499-502
Metrics: Total
Views: 0 (Spandidos Publications: | PMC Statistics: )
Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )
This article is mentioned in:
Abstract
A standard therapeutic approach for advanced malignant thymoma has yet to be defined given the rarity of this condition. We present a patient with advanced thymoma, evaluated as inoperable at diagnosis due to multiple serosal metastases. The strong constitution and determination of the patient allowed treatment with six distinct and subsequent chemotherapy regimens, all administered on an outpatient basis. A survival of 64 months from diagnosis was achieved. A favorable clinical response was obtained after the first three treatment lines, with the disappearance of all lesions on both computed tomography and positron emission tomography (PET) images. However, this result was not confirmed by surgical exploration of the thorax, undertaken with the aim of radical excision of possible residual disease. The presence of multiple pleural nodules, not evident on the imaging techniques, prevented even limited tumor debulking. The chemotherapy lines administered following detection of the lessions, stabilized the disease for a further 2 years, while a satisfactory quality of life was maintained. Only in the last months did the tumor progress and signs of cardiotoxicity appear, with the latter constituting the eventual cause of death. This case is important since the medical literature does not indicate non-cross-resistant regimens for advanced thymoma following second-line chemotherapy, and the sequence of regimens presented in this case study may serve as a feasible outline program. Moreover, we highlight the known possibility of false-negative PET studies, which can occur despite the claimed glucose avidity of thymoma tissue.
View References
1
|
Venuta F, Rendina EA and Coloni GF:
Multimodality treatment of thymic tumors. Thorac Surg Clin.
19:71–81. 2009. View Article : Google Scholar : PubMed/NCBI
|
2
|
Kondo K: Optimal therapy for thymoma. J
Med Invest. 55:17–28. 2008. View Article : Google Scholar
|
3
|
Kim ES, Putnam JB, Komaki R, et al: Phase
II study of a multidisciplinary approach with induction
chemotherapy, followed by surgical resection, radiation therapy,
and consolidation chemotherapy for unresectable malignant thymomas:
final report. Lung Cancer. 44:369–379. 2004. View Article : Google Scholar
|
4
|
Loehrer PJ Sr, Joroutek M, Aisner A, Green
M, Thomas CR Jr, Livingston R and Johnson DH: Combined etoposide,
ifosfamide, and cisplatin in the treatment of patients with
advanced thymoma and thymic carcinoma. Cancer. 91:2010–2015. 2001.
View Article : Google Scholar : PubMed/NCBI
|
5
|
Ogury T, Achiwa H, Kato D, Niimi T, Sato S
and Ueda R: Efficacy of docetaxel as a second-line chemotherapy for
thymic carcinoma. Chemotherapy. 50:279–282. 2004. View Article : Google Scholar : PubMed/NCBI
|
6
|
Wick MR: Prognostic factors for thymic
epithelial neoplasms, with emphasis on tumor staging. Hematol Oncol
Clin N Am. 22:527–542. 2008. View Article : Google Scholar : PubMed/NCBI
|
7
|
Rea F, Marulli G, Giraldi R, Bortolotti L,
Favaretto A, Galligioni A and Sartori F: Long-term survival and
prognostic factors in thymic epithelial tumors. Eur J Chardiothorac
Surg. 26:412–418. 2004. View Article : Google Scholar : PubMed/NCBI
|
8
|
Quint LE: PET: other thoracic
malignancies. Cancer Imaging. 6:S82–S88. 2006. View Article : Google Scholar : PubMed/NCBI
|
9
|
Sung YM, Lee KS, Kim BT, Choi JY, Shim YM
and Yi CA: 18F-FDG PET/CT of thymic epithelial tumors: usefulness
for distinguishing and staging tumor subgroups. J Nucl Med.
47:1628–1634. 2006.PubMed/NCBI
|
10
|
Minotti G, Menna P, Salvatorelli E, Cairo
G and Gianni L: Anthracyclines: molecular advances and
pharmacologic developments in antitumor activity and
cardiotoxicity. Pharmacol Rev. 56:185–229. 2004. View Article : Google Scholar : PubMed/NCBI
|